Clinical and pharmacological group: & nbsp

Cholagogue and bile preparations

Included in the formulation
  • Allochol
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Allochol
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Allochol
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Allochol-UBF
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • АТХ:

    A.05.A.X   Other drugs for the treatment of bile duct diseases

    Pharmacodynamics:The drug acts in several ways:

    - dry bile in the composition of the drug affects the receptors of the intestinal mucosa and the epithelium of the bile ducts. Increases secretory activity of the liver. Improves intestinal secretion and motility. The increase in secretion blocks the upward path of infection through the biliary tract, as bacteria are washed out with bile into the intestine.

    - Activated carbon reduces the processes of fermentation and putrefaction in the intestine, decreases flatulence. Associated with toxins produced by an alien bacterial flora.

    - garlic has anthelminthic, antibacterial action. This allows the drug to be used in the complex treatment of parasitic liver diseases.

    - nettle contains vitamins, minerals (iron), which favorably affects the fat metabolism of man, stimulates the formation of red blood cells.

    - By increasing the osmotic gradient between the blood plasma and bile, it causes an increase in the filtration of electrolytes and water in the bile capillaries. Decreased precipitation of cholesterol, which reduces the likelihood of formation of gallstones.

    - improves digestion by increasing the production of bile, enhancing emulsification of fats in the lumen of the intestine.

    - can serve as a means of replacing bile acids (with their endogenous insufficiency).

    Pharmacokinetics:Not studied.
    Indications:Chronic reactive hepatitis; cholangitis; cholecystitis; biliary dyskinesia; atonic constipation; postcholecystectomy syndrome.

    XI.K55-K63.K59.0   Constipation

    XI.K70-K77.K73   Chronic hepatitis, not elsewhere classified

    XI.K80-K87.K81   Cholecystitis

    XI.K80-K87.K83.0   Cholangitis

    Contraindications:Hypersensitivity to the drug; hepatitis in the acute stage; calculous cholecystitis; obstructive jaundice; peptic ulcer of the stomach and duodenum; acute pancreatitis; pregnancy and the period of breastfeeding (the category of action on the fetus according to the FDA is not defined,since the drug is not represented in the US Pharmacopeia; the safety for the fetus has not been studied, and whether the drug penetrates into breast milk); children under 18 years of age (safety and efficacy not studied).
    Carefully:Cholelithiasis. The drug increases the risk of biliary duct obstruction because of its cholekinetic activity.
    Pregnancy and lactation:It is not recommended for use in pregnant and lactating mothers. The FDA action category is not defined. Well-controlled studies on humans and animals have not been conducted. There is no data on the penetration of the drug into breast milk.
    Dosing and Administration:The maximum daily and single dose is not determined.

    Adults take 1-2 tablets 3-4 times a day after meals. The course of treatment is 3-4 months.

    With exacerbations, 1 tablet is prescribed 2-3 times a day for 1-2 months.

    Use in children

    Special studies on use in children have not been conducted. It is recommended to appoint patients over 18 years of age.

    Side effects:Allergic reactions.

    From the gastrointestinal tract: diarrhea.

    Overdose:Acute drug poisoning and its symptoms are not described.Symptomatic maintenance therapy, withdrawal of the drug before the normalization of the condition is shown.
    Interaction:The combined use of a combination with choleretics of synthetic or plant origin enhances bile formation.

    Taking the drug with fat-soluble vitamins improves the absorption of the latter.

    Use of the drug with chemotherapeutic drugs and antiseptics for infectious processes in the biliary tract and liver increases the effectiveness of the latter.

    Special instructions:With caution appoint the drug to patients with cholelithiasis. They are oriented to the size and localization of gallstones according to ultrasound. The goal is to prevent a possible obstruction of the gallbladder by a stone with increased bile formation and bile secretion.

    The first signs of improvement (disappearance of the pain syndrome, dyspeptic phenomena) appear 6-8 days after the start of the procedure.

    Instructions
    Up